Vueway® (Gadopiclenol) Receives Positive CHMP Opinion

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of the macrocyclic, high-relaxivity Vueway® (Gadopiclenol) in adults and pediatric patients older than 2 years of age.

MILAN, Oct. 12, 2023 /PRNewswire/ -- Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions through a comprehensive portfolio inclusive of precision diagnostic imaging modalities, today received notification that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Vueway® (Gadopiclenol) solution for injection for magnetic resonance imaging (MRI) for use in adult and pediatric patients aged 2 years and older with magnetic resonance imaging (MRI) of the CNS (brain, spine, and surrounding tissues) and several body organs (liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system). The European Commission is expected to issue its decision by the end of 2023.

Vueway® (Gadopiclenol), is a new macrocyclic gadolinium-based contrast agent (GBCA), very stable and with the highest relaxivity among all the other GBCAs on the market today¹, so that its approved dose is exactly half of that approved for other macrocyclic GBCAs for similar indications². It was approved by the United States Food and Drug Administration (US FDA) in September 2022.

"The high relaxivity of Vueway® has shown to allow an improvement of its risk-benefit profile by reducing exposure without compromising imaging performance," said Alberto Spinazzi, MD, Chief Medical and Regulatory Officer at Bracco Imaging. "Vueway® will provide healthcare professionals with an important new option for their patients, as well as for the environment. We eagerly anticipate its arrival to the European market."

The CHMP opinion is based on the results from two prospective, large-scale, randomized, double-blind, crossover clinical studies, PICTURE and PROMISE, conducted in more than 500 adult patients undergoing contrast-enhanced MRI and aimed at comparing the safety and efficacy of 0.05 mmol/kg Gadopiclenol compared with 0.1 mmol/kg Gadobutrol^3,4. The PICTURE trial demonstrated comparable diagnostic efficacy at half dose in MRI of the central nervous system⁵, the PROMISE trial in MRI of the head and neck, chest, breast, liver, pancreas, pelvis organs, and the musculoskeletal system⁶.

Gadopiclenol offers a two-to-three-fold higher relaxivity than available GBCAs¹ for use with any MRI scanner, regardless of field strength. The contrast agent's macrocyclic structure also confers high stability⁷. The end result is adequate diagnostic efficacy at a Vueway® dose which is lower than those approved for other macrocyclic GBCAs in clinical use², while minimizing the risk of gadolinium retention in brain and body tissues, and possibly reducing release of gadolinium in the environment⁷.

About gadolinium-based contrast agents
Gadolinium-based contrast agents (GBCAs) are used in magnetic resonance imaging (MRI) procedures to help enhance the visibility of certain tissues. Gadolinium is a rare earth metal that has unique magnetic properties that make it useful for MRI imaging.

About gadopiclenol
Gadopiclenol, initially invented by Guerbet with subsequent contribution of Bracco IP, is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity. The efficacy and safety of gadopiclenol have been evaluated in MRI of the Central Nervous System, head and neck, thorax, abdomen, pelvis, and musculoskeletal system (For US reference, refer to the approved USPI).

Details on Phase III clinical trials are available on www.ClinicalTrials.gov:

• Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) Full Text View - ClinicalTrials.gov
• Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) Full Text View - ClinicalTrials.gov

About the PICTURE trial¹
The PICTURE trial included 256 patients with known or highly suspected CNS lesion(s). All primary and secondary endpoints of the study were achieved. All blinded readers' evaluations indicated the superiority of the combined unenhanced/contrast-enhanced MRI with 0.05 mmol/kg gadopiclenol over unenhanced MRI alone for all lesion visualisation criteria (p

About the PROMISE trial²
The PROMISE trial included 273 adult patients suspected of having an enhancing abnormality in one of three different body regions (head/neck, breast/thorax/abdomen/pelvis, or musculoskeletal). Off-site blinded readers with expertise in the respective body regions rated border delineation, internal morphology, and visual contrast enhancement. All primary and secondary endpoints of the study were achieved. For all blinded readers, 0.05 mmol/kg gadopiclenol was non-inferior to 0.1 mmol/kg gadobutrol for all visualisation parameters and all readers (P<.001 and superior to unenhanced images two of three readers yielded higher percentage enhancement for gadopiclenol lesion-to-background ratio did not differ. most participants reported no preference between mmol gadobutrol images.>

About Bracco Imaging
Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. The Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Bracco Imaging has approximately 3,700 employees and operates in more than 100 markets globally. Bracco Imaging has a well-skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. R&D activities are located in four centers based in Italy, Switzerland, the United Kingdom and the United States. Bracco Group global revenues were 1.7 billion Euros in 2020. To learn more about Bracco Imaging, visit www.bracco.com.

THE BRACCO IMAGING AND GUERBET COLLABORATION
Bracco Imaging and Guerbet in December 2021 entered a worldwide collaboration on Gadopiclenol manufacturing and research and development activities. Gadopiclenol will be commercialized independently under separate brands. Both Guerbet and Bracco Imaging each own valuable intellectual property on Gadopiclenol. Furthermore, after an agreed transition period when Guerbet manufactures Gadopiclenol for both Guerbet and Bracco, both companies will manufacture the Gadopiclenol active ingredient and finished product.

The strategic collaboration is expected to accelerate access to Gadopiclenol and deliver innovation, as well as better care to patients and caregivers alike.

Bracco Imaging
Micaela Colamasi
PR Manager
[email protected]
+39 348 2314362

¹ Robic C, Port M, Rousseaux O, et al. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium ChelateWith High T1 Relaxivity. Invest Radiol 2019; 54: 475-484.

² https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA0686-003002_15052023150215.pdf
https://www.medicines.org.uk/emc/product/14787/smpc
https://www.medicines.org.uk/emc/product/2876/smpc
https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20211118000026
https://www.medicines.org.uk/emc/product/349/smpc#gref

³ https://clinicaltrials.gov/study/NCT03986138?intr=gadopiclenol&rank=8

⁴ https://clinicaltrials.gov/study/NCT03996447?intr=gadopiclenol&rank=9

⁵ Loevner LA, Kolumban B, Hutóczki G, et al. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial. Invest Radiol. 2023; 58:307-313

⁶ Kuhl C, Csőszi T, Piskorski W, Miszalski T, Lee JM, Otto PM. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI. Radiology 2023; 308: e222612

⁷ Runge VM and Heverhagen, JT. Advocating the Development of Next-Generation High-Relaxivity Gadolinium Chelates for Clinical Magnetic Resonance. Invest Radiol. 2018 Jul;53(7):381-389

View original content to download multimedia:https://www.prnewswire.com/news-releases/vueway-gadopiclenol-receives-positive-chmp-opinion-301955340.html

SOURCE Bracco Group